IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Management Company, LLP and Logos Capital IconOVir formed by team behind Kite Pharma, Allogene Therapeutics and Kronos Bio Proprietary oncolytic virus platform based on technology developed at Salk Institute under the leadership of renowned […]